Shanghai Pharma To Focus On Sales Of Domestic Products
This article was originally published in PharmAsia News
Executive Summary
Shanghai Pharmaceuticals Holding Co. reported that it will continue increasing the proportion of quality domestic drugs in its distribution portfolio, given the larger profit margins and impact of a compliance probe of GlaxoSmithKline and others.